Literature DB >> 16788618

Epidermal growth factor/transforming growth factor alpha receptors and psoriasis.

L E King1, R E Gates, C M Stoscheck, L B Nanney.   

Abstract

The abnormal growth and differentiation in psoriasis is reflected in the abnormal regulation of Epidermal Growth Factor/Transforming Growth Factor Alpha (EGF/TGFalpha) receptor metabolism. In psoriasis and other hyperproliferative skin conditions these receptors are persistently expressed throughout the interfollicular epidermis as long as the growth stimulatory signal persists. One of the first biochemical signs of effective therapy of psoriasis is the return of the EGF/TGFalpha receptor pattern toward the primarily basilar distribution seen in normal human adult skin. Whether the abnormal expression of TGFalpha in the involved skin induces the persistent expression of EGF receptors is not known nor is the signal that causes the increased production of TGFalpha. Studies to determine what factors regulate EGF receptor expression and TGFalpha induction may yield important new insights into the pathogenesis and therapy of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 16788618     DOI: 10.1111/1523-1747.ep12505661

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype.

Authors:  P W Cook; M Piepkorn; C H Clegg; G D Plowman; J M DeMay; J R Brown; M R Pittelkow
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

2.  EGF receptor expression and growth of psoriatic and normal human keratinocytes are modulated by 1.25 (OH)2-vitamin D3 ex vivo.

Authors:  A M Boisseau-Garsaud; P Donatien; C Margerin; A Taïeb
Journal:  Arch Dermatol Res       Date:  1996-07       Impact factor: 3.017

3.  Effects of tiflucarbine as a dual protein kinase C/calmodulin antagonist on proliferation of human keratinocytes and release of reactive oxygen species from human leukocytes.

Authors:  L Hegemann; R Fruchtmann; B Bonnekoh; B H Schmidt; J Traber; G Mahrle; R Müller-Peddinghaus; L A van Rooijen
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

4.  Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.

Authors:  B Neyns; V Meert; F Vandenbroucke
Journal:  Curr Oncol       Date:  2008-08       Impact factor: 3.677

Review 5.  Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.

Authors:  Mark G Lebwohl; Emil A Tanghetti; Linda Stein Gold; James Q Del Rosso; Nelly K Gilyadov; Abby Jacobson
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.